1. |
Chen H, Kim AW, Hsin M, et al. The 2023 American Association for Thoracic Surgery (AATS) expert consensus document: Management of subsolid lung nodules. J Thorac Cardiovasc Surg, 2024. doi:10.1016/j.jtcvs.2024.02.026.
|
2. |
National Lung Screening Trial Research, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409.
|
3. |
de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med, 2020, 382(6): 503-513.
|
4. |
Yankelevitz DF, Yip R, Smith JP, et al. CT screening for lung cancer: Nonsolid nodules in baseline and annual repeat rounds. Radiology, 2015, 277(2): 555-564.
|
5. |
MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. Radiology, 2017, 284(1): 228-243.
|
6. |
Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: Frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol, 2002, 178(5): 1053-1057.
|
7. |
Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: A statement from the Fleischner Society. Radiology, 2013, 266(1): 304-317.
|
8. |
Yin J, Xi J, Liang J, et al. Solid components in the mediastinal window of computed tomography define a distinct subtype of subsolid nodules in clinical stageⅠlung cancers. Clin Lung Cancer, 2021, 22(4): 324-331.
|
9. |
Kakinuma R, Noguchi M, Ashizawa K, et al. Natural history of pulmonary subsolid nodules: A prospective multicenter study. J Thorac Oncol, 2016, 11(7): 1012-1028.
|
10. |
Zhang Z, Zhou L, Min X, et al. Long-term follow-up of persistent pulmonary subsolid nodules: Natural course of pure, heterogeneous, and real part-solid ground-glass nodules. Thorac Cancer, 2023, 14(12): 1059-1070.
|
11. |
Henschke CI, Yip R, Smith JP, et al. CT Screening for lung cancer: Part-solid nodules in baseline and annual repeat rounds. AJR Am J Roentgenol, 2016, 207(6): 1176-1184.
|
12. |
Li D, Deng C, Wang S, et al. Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative. J Thorac Cardiovasc Surg, 2022, 164(6): 1614-1622.e1.
|
13. |
Cheng X, Onaitis MW, D'Amico TA, et al. Minimally invasive thoracic surgery 3.0: Lessons learned from the history of lung cancer surgery. Ann Surg, 2018, 267(1): 37-38.
|
14. |
Fu F, Zhang Y, Wen Z, et al. Distinct prognostic factors in patients with stage Ⅰ non-small cell lung cancer with radiologic part-solid or solid lesions. J Thorac Oncol, 2019, 14(12): 2133-2142.
|
15. |
Fu F, Chen Z, Chen H. Treating lung cancer: Defining surgical curative time window. Cell Res, 2023, 33(9): 649-650.
|
16. |
Jiang C, Zhang Y, Deng P, et al. The overlooked cornerstone in precise medicine: Personalized postoperative surveillance plan for non-small cell lung cancer. JTO Clinical and Research Report, 2024-06-27.
|
17. |
Ye T, Wu H, Wang S, et al. Radiologic identification of pathologic tumor invasion in patients with lung adenocarcinoma. JAMA Netw Open, 2023, 6(10): e2337889.
|
18. |
Zhang Y, Fu F, Chen H. Management of ground-glass opacities in the lung cancer spectrum. Ann Thorac Surg, 2020, 110(6): 1796-1804.
|
19. |
Zhang Y, Deng C, Zheng Q, et al. Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: A prospective, multicenter, clinical trial. J Thorac Oncol, 18(7): 931-939.
|